NorthWest Biotherapeutics Inc (NWBO)

[FatCat_Banker]

I read it as primary endpoint (necrosis) has been met in the trail's infancy.

I could be wrong. Examining more finite points ...

The hospital, who is leading the abstract, (nor the company) is not required to submit to ASCO. The hospital would only do this for marketing leverage. They would NOT author a negative abstract.

These things are all bullish indicators.

Only two disclaimers were given: the Service Agreements' timelines & Direct could get rejected by ASCO, even if good data is present, due to the immaturity of the study.

L is intriguing.

The company can't debate figures and request extensions. The only entity that can do that is the DMC. The study either, merely, requires more attention, OR, they recommended something that requires subsequent review ...

And, ladies & gentlemen, time has passed the point of termination due to futility/safety. That would've been long ago detected and ruled on.